Advanced Search
LUO Yiyang, FENG Xiaoli. Research Progress on Relation Between CD47 and Immunotherapy on Lymphoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 799-803. DOI: 10.3971/j.issn.1000-8578.2021.21.0253
Citation: LUO Yiyang, FENG Xiaoli. Research Progress on Relation Between CD47 and Immunotherapy on Lymphoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 799-803. DOI: 10.3971/j.issn.1000-8578.2021.21.0253

Research Progress on Relation Between CD47 and Immunotherapy on Lymphoma

  • CD47 is a member of the immunoglobulin superfamily. It is expressed on various cells and tissues of human, but it is more expressed on tumor cells, especially in various hematopoietic tumors. The combination of CD47 expressed on tumor cells with signal regulator protein α (SIRPα) on macrophages inhibits the phagocytosis of tumors by macrophages. The reaction can lead to tumor immune escape. CD47 has become a new hot spot in tumor research. This article reviews the correlation between the structure and expression of CD47, CD47-SIRPα, CD47-targeting antibody drugs and lymphoma immunotherapy.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return